References
- Jovanovic DB, Stosovic MD, Gojakovic BM, et al. Inflammatory markers as mortality predictors in continuous ambulatory peritoneal dialysis patients. Ren Fail. 2015;37:230–236
- Ahmed MS, Jadhav AB, Hassan A, Meng QH. Acute phase reactants as novel predictors of cardiovascular disease. ISRN Inflamm. 2012;2012:953461
- Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis Rheum. 2009;61:1435–1440
- Li G, Ren F, Yao J, Wang M, Feng X, Liu D. Human serum amyloid A (SAA) protein changes in acute epilepsy patients. Int J Neurosci. 2013;123:265–268
- Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid. 2005;12:48–53
- Horiuchi Y, Hirayama S, Soda S, et al. Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. J Atheroscler Thromb. 2010;17:722–729
- Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: Emphasis on the metabolic syndrome. J Am Coll Cardiol. 2006;48:677–685
- Spreafico A, Millucci L, Ghezzi L, et al. Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford). 2013;52:1667–1673